Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
PR Newswire —
Strong Q4 with 76.0 MSEK in revenue, up 135% from Q4 2024. Submission of Biologics License Application (BLA) for imlifidase for highly sensitized patients awaiting kidney transplantation. Successfully completed a directed share issue raising 671.5 MSEK (~ $71.3M). LUND, Sweden, Feb. 11,...